Entropy Technologies LP Sells 15,005 Shares of TG Therapeutics, Inc. $TGTX

Entropy Technologies LP decreased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 24.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 45,410 shares of the biopharmaceutical company’s stock after selling 15,005 shares during the period. Entropy Technologies LP’s holdings in TG Therapeutics were worth $1,509,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Danske Bank A S bought a new position in TG Therapeutics in the 3rd quarter worth $25,000. Hantz Financial Services Inc. grew its stake in shares of TG Therapeutics by 82.7% in the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 560 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of TG Therapeutics by 86.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 573 shares in the last quarter. Truvestments Capital LLC raised its stake in shares of TG Therapeutics by 172.4% in the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 1,026 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new position in TG Therapeutics during the fourth quarter valued at approximately $52,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. HC Wainwright upped their target price on shares of TG Therapeutics from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. B. Riley Financial raised their price target on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a report on Monday. Jefferies Financial Group restated a “buy” rating and issued a $83.00 target price on shares of TG Therapeutics in a report on Monday, June 22nd. Finally, Bank of America increased their target price on shares of TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research note on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $58.50.

TG Therapeutics Trading Down 0.5%

TGTX opened at $55.75 on Tuesday. The stock’s fifty day moving average is $49.34 and its two-hundred day moving average is $38.26. The company has a market capitalization of $8.53 billion, a P/E ratio of 19.49, a PEG ratio of 1.40 and a beta of 1.60. TG Therapeutics, Inc. has a 52 week low of $25.28 and a 52 week high of $59.30. The company has a quick ratio of 5.12, a current ratio of 5.81 and a debt-to-equity ratio of 1.28.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The firm had revenue of $204.92 million during the quarter, compared to analysts’ expectations of $200.33 million. During the same quarter in the prior year, the company posted $0.03 earnings per share. TG Therapeutics’s quarterly revenue was up 69.5% compared to the same quarter last year. Analysts forecast that TG Therapeutics, Inc. will post 1.46 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.